Heather Bresch

Look, I think if you've got a niche portfolio or just operating in one country, like the United States, your ability to absorb the volatility is much less. Not only do we have a differentiated and diversified platform, we're across generic brands as well as over-the-counter medicine. People are starting to understand: all generic companies aren't created equally. We believe Mylan has a unique, global platform that right now is being able to shine. I think this administration is a solution-oriented administration, and this is a huge problem.” said Heather Bresch on this article: Mylan CEO Heather Bresch says diversification is boosting company after EpiPen controversy. This page contains 17 articles quoting Heather Bresch. Main topics on which Heather Bresch is quoted are EpiPen Auto-Injector and Mylan. In addition you’ll find 39 quotes there. All these quotes are mentioned on this page and you can filter them by date and by topics.

Heather Bresch quotes

Automatically powered by

As he said, this is a huge program. And, he said it's complicated. So it's going to have to take bold action to be able to really look at this holistically.

We have over 630 products here in the United States. Last year, we sold 22 billion doses. One out of every 13 scripts in the United States is filled with a Mylan medicine, more than the seven [other] largest pharmaceutical companies combined. The last three years, our company has almost doubled. Look at the global footprint we have today. Fifty percent of our revenues are outside the United States. And inside the United States we are extremely diversified and [have a] differentiated portfolio. We don't have product that makes up more than 5 percent of our revenue.

Look, I think if you've got a niche portfolio or just operating in one country, like the United States, your ability to absorb the volatility is much less. Not only do we have a differentiated and diversified platform, we're across generic brands as well as over-the-counter medicine. People are starting to understand: all generic companies aren't created equally. We believe Mylan has a unique, global platform that right now is being able to shine. I think this administration is a solution-oriented administration, and this is a huge problem.

We fixed EpiPen. We introduced a generic, $300. We cut the price in half. We took action with EpiPen. It's half the price. We're making sure everyone that needs one has one. But, importantly, it showed that the system is broken.

I am optimistic with this administration. … I think this administration is solution oriented.

The pricing model has got to change. If anybody is walking away from this conference thinking it's business as usual, that's a mistake.

I truly understand the outrage when you have no idea what something's going to cost. As I step back and try to look at everything ... through this patient lens, it gives a different perspective, and we're continue to apply those learnings.

Looking back, I think EpiPen started a very important and much-needed conversation in the health-care space ... of just how it works. You know, when you look at a system where as the manufacturer, as the seller, the one who is owning EpiPen ... and we make less than half of that list price, I think that demonstrates the imbalance in the system.

Look, I'm extremely optimistic. I believe that obviously he is a very business-minded individual that's very solution-oriented. You look at how the system works today, you can't help but think it's just, it's not rational. We don't have a market-based system for grand pharmaceuticals, and we have a rebate-based system.

And it's about our whole product portfolio. I mean our average sales price was 25 cents a dose. Last year ...one of out of every prescriptions filled as Myan medicine, 21 billion doses. That's more than Pfizer, J&J, Merck, Sanofi and Astra all combined.

Most importantly, if EpiPen started this conversation, I will try at least to do everything in my power to see if through, and seeing it through means changing the way that pharmaceutical pricing, and ... that patient lens needs to change dramatically.

While it is important to understand the outdated and complex system that determines what someone pays for medicine in the U.S., hardworking families don't need an explanation, they need a solution. This is why we took decisive action with our EpiPen product and have launched the first generic version at half the WAC price.

The system needs reinventing across the entire U.S. health care landscape.

The overwhelming majority of what we've spent has been on access and awareness programs.

We understand the deep frustration and concerns associated with the cost of EpiPen to the patient, and have always shared the public's desire to ensure that this important product be accessible to anyone who needs it.

We have been a long-term, committed partner to the allergy community and are taking immediate action to help ensure that everyone who needs an EpiPen Auto-Injector gets one. We recognize the significant burden on patients from continued, rising insurance premiums and being forced increasingly to pay the full list price for medicines at the pharmacy counter.

We've put hundreds of millions of dollars behind it.

We do subsidize the rest of the world ...and as a country we've made a concious decision to do that. And I think the world's a better place for it.

The patient is paying twice. They're paying full retail price at the counter, and they're paying higher premiums on their insurance. It was never intended that a consumer, that the patients would be paying list price, never. The system wasn't built for that.

What Mylan takes from that, our net sales is $274, so $137 per pen.

People don't understand their coverage – and how could they? It's complicated. This isn't a Mylan issue. This is a health-care issue.

Congress and the leaders of this country need to quit putting their toe in this topic and really fix this – we have an outdated system. The patient is paying twice.

Mylan is taking "immediate action" to ensure availability of EpiPens.

She had. I certainly to this day believe I did everything I needed to do to get my degree.

Despite much external focus and discussion of the pricing environment, ... we continue to see nothing out of the ordinary to change our generic pricing assumptions of low- to mid-single digit erosion for the full year.

No quotes...
More Heather Bresch quotes
|< <
{{currentQuotePage}}/{{numberPage}}
> >|
<
>